- Who can participate: Eligible participants are adults aged 18-65 with a confirmed diagnosis of the condition under study. Exclusion criteria include any significant comorbidities or contraindications to the investigational medication.
- Study details: The study is a randomized, double-blind, placebo-controlled trial. Participants will receive either the investigational medication or a placebo for a duration of 12 weeks. The primary endpoint is the change in symptom severity from baseline to the end of the study.